Skip to main content
SpringerLink
Log in

OM-85 BV, an immunostimulant in pediatric recurrent respiratory tract infections: a systematic review

  • Systematic Review
  • Published:
World Journal of Pediatrics Aims and scope Submit manuscript

Abstract

Background

This study was conducted to assess the efficacy of OM-85 BV (Broncho-Vaxom) in the prevention of pediatric recurrent respiratory tract infections (RTIs). Available evidence suggests that defining recurrent RTIs as ≥3 infections per fall-winter semester is both medically and epidemiologically justified. Therefore, this criterion was chosen as a primary endpoint.

Methods

Trials were identified through consultation of bibliographic databases and other channels. Eleven non-blinded studies plus one dealing with primary prevention were excluded and eight randomized controlled trials were included in the meta-analysis. The data were compared at 6 months, which represented the end of most studies. The complete database was examined according to the guidelines of the Cochrane collaboration.

Results

The mean age of children and the number of RTIs in the preceding year were comparable at admission. Of the patients in the OM-85 BV treated population (n=435), 32% had recurrent RTIs (that is, ≥3 RTIs/6 months) vs. 58.2% in the placebo treated population (n=416; P<0.001). Sensitivity analysis showed that this was not driven by any particular trial. The results of this review were also positive for the active treatment regarding the secondary variables, which were represented by the number of patients with at least one RTI and the mean number of RTIs.

Conclusions

This meta-analysis shows, as observed in several individual trials, that the population treated with OM-85 BV had significantly and consistently fewer cases of recurrent RTIs. The data suggest that the effect is greater in patients at increased risk of recurrent RTIs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rozy A, Chorostowska-Wynimko J. Bacterial immunostimulants—mechanism of action and clinical application in respiratory diseases. Pneumonol Alergol Pol 2008;76:353–359.

    PubMed  Google Scholar 

  2. Zelle-Rieser C, Ramoner R, Bartsch G, Thurnher M. A clinically approved oral vaccine against pneumotropic bacteria induces the terminal maturation of CD83+ immunostimulatory dendritic cells. Immunol Lett 2001;76:63–67.

    Article  CAS  PubMed  Google Scholar 

  3. Emmerich B, Emslander HP, Pachmann K, Hallek M, Milatovic D, Busch R. Local immunity in patients with chronic bronchitis and the effects of a bacterial extract, Broncho-Vaxom, on T lymphocytes, macrophages, gamma-interferon and secretory immunoglobulin A in bronchoalveolar lavage fluid and other variables. Respiration 1990;57:90–99.

    Article  CAS  PubMed  Google Scholar 

  4. Emmerich B, Pachmann K, Milatovic D, Emslander HP. Influence of OM-85-BV on different humoral and cellular immune defense mechanisms of the respiratory tract. Respiration 1992;59Suppl 3:19–23.

    Article  PubMed  Google Scholar 

  5. Schaad UB. Prevention of paediatric respiratory tract infections: emphasis on the role of OM-85. Eur Respir Rev 2005;14:74–77.

    Article  Google Scholar 

  6. Illi S, von Mutius E, Lau S, Bergmann R, Niggemann B, Sommerfeld C, et al. Early childhood infectious diseases and the development of asthma up to school age: a birth cohort study. BMJ 2001;322:390–395.

    Article  CAS  PubMed  Google Scholar 

  7. Pavia-Ruz N, Lopez P, Santos JI. Recurrent respiratory infection in children: its clinical and laboratory evaluation. Bol Med Hosp Infant Mex 1991;48:385–397.

    CAS  PubMed  Google Scholar 

  8. von Mutius E, Illi S, Hirsch T, Leupold W, Keil U, Weiland SK. Frequency of infections and risk of asthma, atopy and airway hyperresponsiveness in children. Eur Respir J 1999;14:4–11.

    Article  Google Scholar 

  9. Lina B, Valette M, Foray S, Luciani J, Stagnara J, See DM, et al. Surveillance of community-acquired viral infections due to respiratory viruses in Rhone-Alpes (France) during winter 1994 to 1995. J Clin Microbiol 1996;34:3007–3011.

    CAS  PubMed  Google Scholar 

  10. Lopez-Yap A, Abdelnour A, Lomonte B, Porras O. Serum antibody response to polysaccharides in children with recurrent respiratory tract infections. Clin Diagn Lab Immunol 2001;8:1012–1014.

    CAS  PubMed  Google Scholar 

  11. Schaad UB, Mutterlein R, Goffin H. Immunostimulation with OM-85-BV in children with recurrent infections of the upper respiratory tract: a double-blind, placebo-controlled multicenter study. Chest 2002;122:2042–2049.

    Article  PubMed  Google Scholar 

  12. Alho OP, Koivu M, Sorri M, Rantakallio P. Risk factors for recurrent acute otitis media and respiratory infection in infancy. Int J Pediatr Otorhinolaryngol 1990;19:151–161.

    Article  CAS  PubMed  Google Scholar 

  13. van Woensel JB, van Aalderen WM, Kimpen JL. Viral lower respiratory tract infection in infants and young children. BMJ 2003;327:36–40.

    Article  PubMed  Google Scholar 

  14. Del-Rio-Navarro BE, Gonzalez-Diaz S, Escalante-Dominguez AJ, Blandon-Vijil V. Immunostimulants in the prevention of respiratory infections. Int J Biotechnol 2007;9:246–260.

    Article  Google Scholar 

  15. Collet JP, Boissel JP. OM-85 BV: primary versus secondary prevention. Respiration 1994;61Suppl 1:20–23.

    Article  PubMed  Google Scholar 

  16. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. (Available from: www.cochrane-handbook.org)

  17. Ahrens J, Wiedenbach M. Efficacy of the immunostimulant Broncho-Vaxom. Schweiz Med Wochenschr 1984;114:932–934.

    CAS  PubMed  Google Scholar 

  18. Chen ZG, Ji JZ, Li M, Chen YF, Chen FH, Chen H. Immunoregulants improves the prognosis of infants with wheezing. Nan Fang Yi Ke Da Xue Xue Bao 2007;27: 1612–1613.

    CAS  PubMed  Google Scholar 

  19. Collet JP, Ducruet T, Kramer MS, Haggerty J, Floret D, Chomel JJ, et al. Stimulation of nonspecific immunity to reduce the risk of recurrent infections in children attending day-care centers. The Epicreche Research Group. Pediatr Infect Dis J 1993;12:648–652.

    Article  CAS  PubMed  Google Scholar 

  20. Field J, Gómez-Barreto D, Del-Rio-Navarro BE, Berber A. Use of OM-85 BV in the primary prevention of acute respiratory tract infections in children in orphanages. Cur Ther Res 1998;59:407–418.

    Article  CAS  Google Scholar 

  21. Gutiérrez-Tarango MD, Berber A. Efficacy of a bacterial extract (OM-85 BV) in preventing recurrent respiratory tract infections in susceptible children. Clin Drug Investig 1997;13:76–84.

    Article  PubMed  Google Scholar 

  22. Kapellerova A, Sulko M, Krovinova A, Jakubovska M, Michalickova J, Mazarikova O. Immunologic indicators in the treatment of recurrent respiratory diseases using peroral bacterial vaccines. Cesk Pediatr 1989;44:454–458.

    CAS  PubMed  Google Scholar 

  23. Maestroni GJ, Losa GA. Clinical and immunobiological effects of an orally administered bacterial extract. Int J Immunopharmacol 1984;6:111–117.

    Article  CAS  PubMed  Google Scholar 

  24. Martin du Pan RE, Martin du Pan RC. Clinical Study concerning the prevention of infections of the upper respiratory tract of preschool children. Schweiz Rundsch Med Prax 1982:71:1385–1389.

    CAS  PubMed  Google Scholar 

  25. Quezada A, Maggi L, Perez MA, Rodriguez J. Effect of bacterial antigen lysate on IgG and IgA levels in children with recurrent infections and hypogammaglobulinemia. J Investig Allergol Clin Immunol 1999;9:178–182.

    CAS  PubMed  Google Scholar 

  26. Ziuzio S, Sakson B. Vaccine therapy in the treatment of nasal and sinus bacterial allergies. Wiad Lek 1994;47:510–513.

    CAS  PubMed  Google Scholar 

  27. Del-Rio-Navarro BE, Luis Sienra-Monge JJ, Berber A, Torres-Alcántara S, Avila-Castañón L, Gómez-Barreto D. Use of OM-85 BV in children suffering from recurrent respiratory tract infections and subnormal IgG subclass levels. Allergol Immunopathol (Madr) 2003;31:7–13.

    Article  CAS  Google Scholar 

  28. Gomez Barreto D, De la Torre C, Alvarez A, Faure A, Berber A. Safety and efficacy of OM-85-BV plus amoxicillin/clavulanate in the treatment of subacute sinusitis and the prevention of recurrent infections in children. Allergol Immunopathol (Madr) 1998;26:17–22.

    CAS  Google Scholar 

  29. Gutiérrez-Tarango MD, Berber A. Safety and efficacy of two courses of OM-85 BV in the prevention of respiratory tract infections in children during 12 months. Chest 2001;119: 1742–1748.

    Article  PubMed  Google Scholar 

  30. Jara-Perez JV, Berber A. Primary prevention of acute respiratory tract infections in children using a bacterial immunostimulant: a double-masked, placebo-controlled clinical trial. Clin Ther 2000;22:748–759.

    Article  CAS  PubMed  Google Scholar 

  31. Paupe J. Immunotherapy with an oral bacterial extract (OM-85) for upper respiratory infections. Respiration 1991;58:150–154.

    Article  CAS  PubMed  Google Scholar 

  32. Schaad UB, Farine JC, Fux TH. Prospective placebo-controlled double-blind study using a bacterial lysate in infections of the respiratory tract and ENT region in children. Helv Paediatr Acta 1986;41:7–17.

    CAS  PubMed  Google Scholar 

  33. Zagar S, Löfler-Badzek D. Broncho-Vaxom in children with rhinosinusitis: a double-blind clinical trial. ORL J Otorhinolaryngol Relat Spec 1988;50:397–404.

    CAS  PubMed  Google Scholar 

  34. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1–12.

    Article  CAS  PubMed  Google Scholar 

  35. Bland M. An introduction to medical statistics. Oxford: Oxford Medical Publishing Ed., 1995: 235–238, 323–326.

    Google Scholar 

  36. Walfish S. A Review of Statistical Outlier Methods. Pharmaceutical Technology, 2006. http://pharmtech.findpharma.com/pharmtech/article/articleDetail.jsp?id= 384716 (accessed July 8, 2008).

  37. Steurer-Stey C, Lagler L, Straub DA, Steurer J, Bachmann LM. Oral purified bacterial extracts in acute respiratory tract infections in childhood: a systematic quantitative review. Eur J Pediatr 2007;166:365–376.

    Article  PubMed  Google Scholar 

  38. De la Torre González C, Pacheco Ríos A, Escalante Domínguez AJ, del Río Navarro BE. Comparative meta-analysis of immunoestimulant agents used in pediatric patients in Mexico. Rev Alerg Mex 2005;52:25–38.

    PubMed  Google Scholar 

  39. Del-Rio-Navarro BE, Espinosa Rosales F, Flenady V, Sienra-Monge JJL. Immunostimulants for preventing respiratory tract infection in children. Cochrane Database Syst Rev 2006;(4): CD004974.

  40. Barden J, Derry S, McQuay H, Moore R. Bias from industry trial funding? A framework, a suggested approach, and a negative result. Pain 2006;121:207–218.

    Article  PubMed  Google Scholar 

  41. Bero L, Oostvogel F, Bacchetti P, Lee K. Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others. PLoS Med 2007;4:e184.

    Article  PubMed  CAS  Google Scholar 

  42. Jørgensen AW, Hilden J, Gøtzsche PC. Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review. BMJ 2006;333:782.

    Article  PubMed  Google Scholar 

  43. LeLorier J, Grégoire G, Benhaddad A, Lapierre J, Derderian F. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med 1997;337:536–542.

    Article  CAS  PubMed  Google Scholar 

  44. Ioannidis JP, Lau J. Evolution of treatment effects over time: empirical insight from recursive cumulative meta analyses. PNAS 2001;98:831–836.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pediatric Infectious Diseases, University Children’s Hospital, Basel, Switzerland

    Urs B. Schaad

Authors
  1. Urs B. Schaad
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Urs B. Schaad.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schaad, U.B. OM-85 BV, an immunostimulant in pediatric recurrent respiratory tract infections: a systematic review. World J Pediatr 6, 5–12 (2010). https://doi.org/10.1007/s12519-010-0001-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12519-010-0001-x

Key words

Search

Navigation